Enhanced angiogenesis and reduced contraction in thrombospondin-2 - Null wounds is associated with increased levels of matrix metalloproteinases-2 and -9, and soluble VEGF

Journal of Histochemistry and Cytochemistry

Volumn 57, Issue 4, 2009, Pages 301-313

  MacLauchlan, Susan ^a   Skokos, Eleni A ^a   Agah, Azin ^b   Zeng, Jianmin ^a   Tian, Weiming ^a   Davidson, Jeffrey M ^c   Bornstein, Paul ^d   Kyriakides, Themis R ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Angiogenesis; Matrix metalloproteinases; Thrombospondin; VEGF; Wound contraction; Wound healing

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE; GELATINASE A; GELATINASE B; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; COLLAGEN; THROMBOSPONDIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; ISCHEMIA; MOUSE; MYOFIBROBLAST; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WOUND CONTRACTION; WOUND HEALING; ANIMAL; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; FIBROBLAST; GEL; GENETICS; INJURY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN; SMOOTH MUSCLE; SOLUBILITY; TENSILE STRENGTH; VASCULARIZATION;

MUS;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLLAGEN; EXTRACELLULAR MATRIX; FIBROBLASTS; GELS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH; NEOVASCULARIZATION, PHYSIOLOGIC; SKIN; SOLUBILITY; TENSILE STRENGTH; THROMBOSPONDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 63849185760     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/jhc.2008.952689     Document Type: Article

References (60)

1. Adams JC (2001) Thrombospondins: multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 17:25-51
2. Agah A, Kyriakides TR, Bornstein P (2005) Proteolysis of cell-surface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice. Am J Pathol 167: 81-88
3. Agah A, Kyriakides TR, Lawler J, Bornstein P (2002) The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 161:831-839
4. Agah A, Kyriakides TR, Letrondo N, Bjorkblom B, Bornstein P (2004) Thrombospondin 2 levels are increased in aged mice: consequences for cutaneous wound healing and angiogenesis. Matrix Biol 22:539-547
5. Agren MS,Mirastschijski U, Karlsmark T, Saarialho-Kere UK (2001) Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp Dermatol 10: 337-348
6. Armstrong LC, Bjorkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P (2002) Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 13:1893-1905
7. Bein K, Simons M (2000) Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J Biol Chem 275:32167-32173
8. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R (2003) Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63:5224-5229
9. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, et al. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737-744
10. Birner P, Ritzi M, Musahl C, Knippers R, Gerdes J, Voigtlander T, Budka H, et al. (2001) Immunohistochemical detection of cell growth fraction in formalin-fixed and paraffin-embedded murine tissue. Am J Pathol 158:1991-1996
11. Bornstein P (2001) Thrombospondins as matricellular modulators of cell function. J Clin Invest 107:929-934
12. Bradshaw AD, Reed MJ, Sage EH (2002) SPARC-null mice exhibit accelerated cutaneous wound closure. J Histochem Cytochem 50:1-10
13. Bullard KM, Lund L, Mudgett JS, Mellin TN, Hunt TK, Murphy B, Ronan J, et al. (1999a) Impaired wound contraction in stromelysin-1-deficient mice. Ann Surg 230:260-265
14. Bullard KM, Mudgett J, Scheuenstuhl H, Hunt TK, Banda MJ (1999b) Stromelysin-1-deficient fibroblasts display impaired contraction in vitro. J Surg Res 84:31-34
15. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269-285
16. Chen H, Strickland DK, Mosher DF (1996) Metabolism of thrombospondin 2. Binding and degradation by 3t3 cells and glycosaminoglycan-variant Chinese hamster ovary cells. J Biol Chem 271:15993-15999
17. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, Kronberger A, et al. (1988) H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 263:6579-6587
18. Ehrlich HP, Needle AL (1983) Wound healing in tight-skin mice: delayed closure of excised wounds. Plast Reconstr Surg 72:190-198
19. Gill SE, ParksWC(2008)Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 40:1334-1347
20. Godyna S, Liau G, Popa I, Stefansson S, Argraves WS (1995) Identification of the low density lipoprotein receptor-related protein (LRP) as an endocytic receptor for thrombospondin-1. J Cell Biol 129:1403-1410
21. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J (2007) Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipo-protein receptor-related protein-1 (LRP-1). J Cell Physiol 210: 807-818
22. Grinnell F (1994) Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol 124:401-404
23. Grinnell F (2003) Fibroblast biology in three-dimensional collagen matrices. Trends Cell Biol 13:264-269
24. Guo N, KrutzschHC, Inman JK, Roberts DD (1997) Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57:1735-1742
25. Haas TL, Davis SJ, Madri JA (1998) Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 273:3604-3610
26. Heissig B, Hattori K, Friedrich M, Rafii S, Werb Z (2003) Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol 10:136-141
27. Hollander DA, Erli HJ, Theisen A, Falk S, Kreck T, Muller S (2003) Standardized qualitative evaluation of scar tissue properties in an animal wound healing model. Wound Repair Regen 11:150-157
28. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6:41-48
29. Kokenyesi R, Armstrong LC, Agah A, Artal R, Bornstein P (2004) Thrombospondin 2 deficiency in pregnant mice results in premature softening of the uterine cervix. Biol Reprod 70:385-390
30. Krady MM, Zeng J, Yu J, Maclauchlan S, Skokos EA, Tian W, Bornstein P, et al. (2008) Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol 173:879-891
31. Kyriakides TR, Bornstein P (2003) Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 90:986-992
32. Kyriakides TR, Cheung CY, Murthy N, Bornstein P, Stayton PS, Hoffman AS (2002) pH-sensitive polymers that enhance intracellular drug delivery in vivo. J Control Release 78:295-303
33. Kyriakides TR, Hartzel T, Huynh G, Bornstein P (2001a) Regulation of angiogenesis and matrix remodeling by localized, matrix-mediated antisense gene delivery. Mol Ther 3:842-849
34. Kyriakides TR, Leach KJ,HoffmanAS, Ratner BD, Bornstein P (1999a) Mice that lack the angiogenesis inhibitor, thrombospondin 2,mount an altered foreign body reaction characterized by increased vascularity. Proc Natl Acad Sci USA 96:4449-4454
35. Kyriakides TR, Tam JW, Bornstein P (1999b) Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 113:782-787
36. Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, Danielson KG, et al. (1998) Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol 140:419-430
37. Kyriakides TR, Zhu YH, Yang Z, Huynh G, Bornstein P (2001b) Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 159:1255-1262
38. Lawler J (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6:1-12
39. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681-691
40. Lopes N, Gregg D, Vasudevan S, Hassanain H, Goldschmidt-Clermont P, Kovacic H (2003) Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling. Mol Cell Biol 23:5401-5408
41. Madlener M (1998) Differential expression of matrix metalloproteinases and their physiological inhibitors in acute murine skin wounds. Arch Dermatol Res 290(suppl):S24-29
42. Madlener M, Parks WC, Werner S (1998) Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res 242:201-210
43. Mikhailenko I, Kounnas MZ, Strickland DK (1995) Low density lipo-protein receptor-related protein/alpha 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. A process facilitated by cell-surface proteoglycans. J Biol Chem 270:9543-9549
44. Mirastschijski U, Haaksma CJ, Tomasek JJ, Agren MS (2004) Matrix metalloproteinase inhibitor GM 6001 attenuates keratinocyte migration, contraction and myofibroblast formation in skin wounds. Exp Cell Res 299:465-475
45. Mirastschijski U, Impola U, Karsdal MA, Saarialho-Kere U, Agren MS (2002) Matrix metalloproteinase inhibitor BB-3103 unlike the serine proteinase inhibitor aprotinin abrogates epidermal healing of human skin wounds ex vivo. J Invest Dermatol 118:55-64
46. Moses MA,MarikovskyM,Harper JW, Vogt P, Eriksson E, Klagsbrun M, Langer R (1996) Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem 60:379-386
47. Murphy-Ullrich JE (2001) The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest 107:785-790
48. Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ (2000) Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 37:209-218
49. Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P (2008) Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell 19:563-571
50. Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672
51. Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8:221-233
52. Parks WC (1999) Matrix metalloproteinases in repair. Wound Repair Regen 7:423-432
53. Ra HJ, Parks WC (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol 26:587-596
54. Rhee S, Grinnell F (2007) Fibroblast mechanics in 3D collagen matrices. Adv Drug Deliv Rev 59:1299-1305
55. Schroen B, Heymans S, Sharma U, Blankesteijn WM, Pokharel S, Cleutjens JP, Porter JG, et al. (2004) Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res 95:515-522
56. Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med 341:738-746
57. Werb Z, Vu TH, Rinkenberger JL, Coussens LM (1999) Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 107:11-18
58. Wu N, Jansen ED, Davidson JM (2003) Comparison of mouse matrix metalloproteinase 13 expression in free-electron laser and scalpel incisions during wound healing. J Invest Dermatol 121:926-932
59. Yamada E, Tobe T, Yamada H, Okamoto N, Zack DJ, Werb Z, Soloway PD, et al. (2001) TIMP-1 promotes VEGF-induced neovascularization in the retina. Histol Histopathol 16:87-97
60. Yang Z, Kyriakides TR, Bornstein P (2000) Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol Biol Cell 11:3353-3364